A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
← catalyst calendarNCT07165002 · readout ≤ 12 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
32estimated
Sites
3
Countries
Hungary, New Zealand, Slovakia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-20 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy
- Hepatic Insufficiency
Intervention
- Drug: LY3537031
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3537031
measured Baseline to Study Completion (Up to 8 Weeks)
PK: Maximum Concentration (Cmax) of LY3537031
measured Baseline to Study Completion (Up to 8 Weeks)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed